Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/TP53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study

被引：4

作者：

Mauro, Francesca Romana ^{[1
]}

Tedeschi, Alessandra ^{[2
]}

Piciocchi, Alfonso ^{[3
]}

Motta, Marina ^{[4
]}

Iannella, Emilia ^{[5
]}

Farina, Lucia ^{[6
]}

Scarfo, Lydia ^{[7
,8
]}

Marasca, Roberto ^{[9
]}

Coscia, Marta ^{[10
]}

Cortelezzi, Agostino ^{[11
]}

Laurenti, Luca ^{[12
]}

Melpignano, Angela ^{[13
]}

Zinzani, Pier Luigi ^{[14
]}

Molica, Stefano ^{[15
]}

Re, Francesca ^{[16
]}

Andriani, Alessandro ^{[17
]}

Vincelli, Donatella Iolanda ^{[18
,19
]}

Visco, Carlo ^{[20
]}

Gozzetti, Alessandro ^{[21
]}

Orlandi, Ester Maria ^{[22
]}

Trentin, Livio ^{[23
]}

Tani, Monica ^{[24
]}

Califano, Catello ^{[25
]}

Tagariello, Giuseppe ^{[26
]}

Ghia, Paolo ^{[7
,8
]}

Caputo, Maria Denise ^{[27
]}

Salaroli, Adriano ^{[27
]}

Innocenti, Idanna ^{[12
]}

Frustaci, Anna ^{[28
]}

Vitale, Candida ^{[10
]}

Petulla, Marta ^{[29
]}

de Fabritiis, Paolo ^{[5
]}

Vignetti, Marco ^{[3
,27
]}

Fazi, Paola ^{[3
]}

Foa, Robin ^{[30
]}

机构：

[1] Sapienza Univ, Dept Cellular Biotechnol & Hematol, Hematol, Rome, Italy

[2] Osped Niguarda Ca Granda, Dept Hematol, Niguarda Canc Ctr, Milan, Italy

[3] Fdn GIMEMA, Rome, Italy

[4] Spedali Civil Brescia, Dept Hematol, Brescia, Italy

[5] Tor Vergata Univ, S Eugenio Hosp, Dept Hematol, Rome, Italy

[6] Fdn IRCCS Ist Nazl Tumori, Dept Hematol, Milan, Italy

[7] Univ Vita Salute San Raffaele, Strateg Res Programm CLL, Milan, Italy

[8] IRCCS Ist Scientifico San Raffaele, Milan, Italy

[9] Univ Modena & Reggio Emilia, Dept Med & Surg Sci, Hematol Unit, Modena, Italy

[10] AUO Citta Salute & Scienza Torino, Div Hematol, Turin, Italy

[11] Fdn Ca Granda IRCCS Osped Maggiore Policlin, OncoHematol Unit, Milan, Italy

[12] Cathol Univ, Inst Hematol, Sacred Heart, Rome, Italy

[13] Osped A Perrino, Brindisi, Italy

[14] Univ Bologna, Inst Hematol LeA Seragnoli, Bologna, Italy

[15] Azienda Ospedaliera Pugliese Ciaccio, Dept Hematol Oncol, Catanzaro, Italy

[16] Azienda Ospedaliero Univ Parma, Hematol & Bone Marrow Transplantat, Parma, Italy

[17] Nuovo Regina Margherita Hosp, Hematol, Rome, Italy

[18] Azienda Ospedaliera Bianchi Melacrino Morelli, Hematol, Reggio Di Calabria, Italy

[19] GIMEMA, Italian Multiple Myeloma Network, Rome, Italy

[20] San Bortolo Hosp, Dept cell therapy & hematol, Vicenza, Italy

[21] Univ Siena, Hematol, Siena, Italy

[22] Fdn IRCCS Policlin San Matteo, Hematol Hunit, Pavia, Italy

[23] Univ Padua, Dept Med, Hematol & Clin Immunol Branch, Sch Med, Padua, Italy

[24] Santa Maria Croci Hosp, Hematol Unit, Ravenna, Italy

[25] Nocera Pagani, Onco Hematol Unit, Pagani, Italy

[26] Hemophilia & Reg Blood Dis Ctr, Hematol Transfus Serv, Castelfranco Veneto, Italy

[27] Sapienza Univ, Dept Cellular Biotechnol & Hematol, Rome, Italy

[28] Osped Niguarda Ca Granda, Dept Hematol, Milan, Italy

[29] ASST Spedali Civili Brescia, Hematol, Brescia, Italy

[30] Sapienza Univ, Dept Cellular Biotechnol & Hematol, Policlin Umberto, Rome, Italy

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.2038.2038

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2038

引用

页数：5

共 27 条

[1] Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib within a Named Patient Program (NPP) in Italy. a Real-Life Retrospective Study
Mauro, Francesca Romana
Soddu, Stefano
Frustaci, Annamaria Maria
Orsucci, Lorella
Motta, Marina
Scarfo, Lydia
Zinzani, Pier Luigi
Falzetti, Franca
Farina, Lucia
Marasca, Roberto
Cortelezzi, Agostino
Carlo-Stella, Carmelo
Molica, Stefano
Coscia, Marta
Zaja, Francesco
Laurenti, Luca
de Fabritiis, Paolo
Gaidano, Gianluca
Gobbi, Marco
Tani, Monica
Di Renzo, Nicola
Fazi, Paola
Vignetti, Marco
Cuneo, Antonio
Foa, Robin
BLOOD, 2018, 132
[2] No benefit from adding rituximab to ibrutinib in relapsed or refractory chronic lymphocytic leukemia or 17p deletion/TP53 mutation
Calleja, Anne
HEMATOLOGIE, 2019, 25 (03): : 131 - 132
[3] Relative efficacy of systemic treatments for patients with relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis according to 17p deletion/TP53 mutations
Kim, Jinchul
Cho, Jinhyun
Lim, Joo Han
Lee, Moon Hee
BLOOD RESEARCH, 2025, 60 (01)
[4] 17P deletion and TP53 gene mutation (17P/TP53) testing behaviour and treatment patterns for chronic lymphocytic leukemia (CLL) patients in France, Germany, Italy, Spain and UK (EU5)
Canta, F. A. Bermudez
Mitrofan, L.
Karanis, Y. B.
Mistry, H.
Anger, C.
ANNALS OF ONCOLOGY, 2016, 27
[5] DOSE DENSE HIGH DOSE METHYLPREDNISOLONE (HDMP) AND RITUXIMAB (RTX) ARE EFFECTIVE IN RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION (17P DEL) / TP53 MUTATION
Pileckyte, R.
Valceckiene, V.
Zvirblis, T.
Griskevicius, L.
HAEMATOLOGICA, 2012, 97 : 525 - 526
[6] Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion
Cavazzini, Francesco
Lista, Enrico
Quaglia, Francesca Maria
Formigaro, Luca
Cavallari, Maurizio
Martinelli, Sara
Rigolin, Gian Matteo
Foa, Robin
Cuneo, Antonio
LEUKEMIA & LYMPHOMA, 2016, 57 (11) : 2685 - 2688
[7] Treatment Outcomes Among Chronic Lymphocytic Leukemia Patients with 17p Deletion or TP53 Mutation in Argentina: A Retrospective Chart Review
Pavlovsky, Miguel A.
Sail, Kavita
Chaves, Leonardo Passos
Kamalakar, Rajesh
Ma, Xiaojing
Brandalise, Patricia
Chiattone, Carlos
BLOOD, 2017, 130
[8] Economic evaluation for the US of venetoclax (VEN) versus ibrutinib (IBR) versus allogeneic hematopoietic stem-cell transplantation (HSCT) for patients (pts) with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) with 17p deletion (del 17p).
Alsaid, Nimer
McBride, Ali
Persky, Daniel Oscar
Anwer, Faiz
Andritsos, Leslie Ann
Kumar, Abhijeet
Yun, Seongseok
Babiker, Hani M.
Abraham, Ivo
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[9] Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study
Visentin, Andrea
Mauro, Francesca Romana
Cibien, Francesca
Vitale, Candida
Reda, Gianluigi
Fresa, Alberto
Ciolli, Stefania
Pietrasanta, Daniela
Marchetti, Monia
Murru, Roberta
Gentile, Massimo
Rigolin, Gian Matteo
Quaglia, Francesca Maria
Scarfo, Lydia
Sportoletti, Paolo
Pravato, Stefano
Piazza, Francesco
Coscia, Marta
Laurenti, Luca
Molica, Stefano
Foa, Robin
Cuneo, Antonio
Trentin, Livio
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (03) : E95 - E99
[10] EVALUATION OF 243 PATIENTS WITH DELETION 17P CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH IBRUTINIB: A CROSS-STUDY ANALYSIS OF TREATMENT OUTCOMES
Jones, J.
Coutre, S.
Byrd, J. C.
Furman, R.
Hillmen, P.
Mato, A.
Osterborg, A.
Tam, C.
Stilgenbauer, S.
Wierda, W.
Heerema, N.
Eckert, K.
Clow, F.
Zhou, C.
Chu, A.
James, D.
O'Brien, S.
HAEMATOLOGICA, 2016, 101 : 150 - 150

← 1 2 3 →